One emerging translational application of the gut microbiome is its potential as a diagnostic and/or prognostic biomarker or as a therapeutic target. Creative Biolabs has developed a platform for gut microbial biomarker discovery. The gut microbial biomarker is identified through immunoprecipitation and mass spectrometry, which supports an easy workflow from sample collection to the final statistical analysis.
Our bodies coexist with vast populations of microbial and the most abundant and diverse variety of microbial habitats reside in the distal gut. In the training of host immunity, controlling gut endocrine function and neurological signaling, digesting food, altering drug action and metabolism, removing toxins, and producing various compounds that affect the host. Reduced gut-microbial diversity (“gut dysbiosis”) has been associated with a number of detrimental health outcomes, including severe mental illness and chronic fatigue. Therefore understanding of gut microbiome’s distinguished features may help in the diagnosis of microbiome-related diseases. Gut microbiota is emerging as a new diagnostic and prognostic marker and/or therapeutic target in diseases.
Fig.1 Microbial dysbiosis and diseases. (Srivastava, 2021)
Direct analysis via mass spectrometry involves the in vivo microbial antigen discovery (InMAD) platform. The InMAD approach includes:
And the sample is analyzed by:
Fig.2 Workflow of analysis via mass spectrometry.
Proteins analysis includes an enrichment step using immunoprecipitation prior to mass spectrometry. Proteins from some biosamples may be at a concentration below the limit of detection by mass spectrometry. To enhance the prospect of detecting the proteins by mass spectrometry, immunoprecipitation is utilized to enrich samples for antigenic biomarkers. Different proteins can be identified from immunoprecipitation experiments from each sample, decreasing the likelihood that a protein was pull-downed through non-specific binding. Immunoprecipitated proteins are precipitated with a chloroform-methanol extraction followed by trypsin digest. Finally, the trypsin-digested peptides from each sample are analyzed by liquid chromatography-mass spectrometry.
With years of experience in assay design and sample processing, Creative Biolabs provides a full range of services for your microbiome research needs. Based on our advanced Gut Microbiota-Based Diagnostics Platform, our microbiome services experts offer biomarker analysis services to support your research of the gut microbiome. If you are interested in our service, please contact us for more information.
References
For Research Use Only | Not For Clinical Use
Download our brochure